ScholarIQanswers from OpenAlex & ORCID
Toshihiko Doi
ResearcherPublications, citations & collaboration network
Toshihiko Doi is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Toshihiko Doi have?
ScholarIQindexed works
Toshihiko Doi has 833 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Toshihiko Doi have?
ScholarIQcitation count
Toshihiko Doi has 30,345 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Toshihiko Doi?
ScholarIQh-index
Toshihiko Doi has an h-index of 73 in OpenAlex.
What is the i10-index of Toshihiko Doi?
ScholarIQi10-index
Toshihiko Doi has an i10-index of 272 in OpenAlex.
What is the ORCID of Toshihiko Doi?
ScholarIQorcid
The ORCID for Toshihiko Doi is on the source record.
What is the OpenAlex record for Toshihiko Doi?
ScholarIQopenalex
The OpenAlex for Toshihiko Doi is on the source record.
What are the most-cited papers on Toshihiko Doi?
ScholarIQmost cited works
Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study
Jong‐Mu Sun, Lin Shen, Manish A. Shah, Peter C. Enzinger, Antoine Adenis, Toshihiko Doi, Takashi Kojima, Jean‐Philippe Metges, Zhigang Li, Sung‐Bae Kim, Byoung Chul Cho, Wasat Mansoor, Shau-Hsuan Li, Patrapim Sunpaweravong, María Maqueda, Eray Goekkurt, Hiroki Hara, Luís Carlos Moreira Antunes, Christos Fountzilas, Akihito Tsuji, Victor Castro Oliden, Qi Liu, Sukrut Shah, Pooja Bhagia, Ken Kato
Randomized Phase III KEYNOTE-181 Study of Pembrolizumab Versus Chemotherapy in Advanced Esophageal Cancer
Takashi Kojima, Manish A. Shah, Kei Muro, Éric François, Antoine Adenis, Chih‐Hung Hsu, Toshihiko Doi, Toshikazu Moriwaki, Sung‐Bae Kim, Se‐Hoon Lee, Jaafar Bennouna, Ken Kato, Lin Shen, Peter C. Enzinger, Shukui Qin, Paula Ferreira, Jia Chen, Gustavo Girotto, Christelle de la Fouchardière, Hélène Senellart, Raed Moh’d Taiseer Al-Rajabi, Florian Lordick, Ruixue Wang, Shailaja Suryawanshi, Pooja Bhagia, Soonmo Peter Kang, Jean‐Philippe Metges, on behalf of the KEYNOTE-181 Investigators
Lactic acid promotes PD-1 expression in regulatory T cells in highly glycolytic tumor microenvironments
Shogo Kumagai, Shohei Koyama, Kota Itahashi, Tokiyoshi Tanegashima, Yi-Tzu Lin, Yosuke Togashi, Takahiro Kamada, Takuma Irie, Genki Okumura, Hidetoshi Kono, Daisuke Ito, Rika Fujii, Sho Watanabe, Atsuo Sai, Shota Fukuoka, Eri Sugiyama, Go Watanabe, Takuya Owari, Hitomi Nishinakamura, Daisuke Sugiyama, Yuka Maeda, Akihito Kawazoe, Hiroki Yukami, Keigo Chida, Yuuki Ohara, Tatsuya Yoshida, Yuki Shinno, Yuki Takeyasu, Masayuki Shirasawa, Kenta Nakama, Keiju Aokage, Jun Suzuki, Genichiro Ishii, Takeshi Kuwata, Naoya Sakamoto, Masahito Kawazu, Toshihide Ueno, Taisuke Mori, Naoya Yamazaki, Masahiro Tsuboi, Yasushi Yatabe, Takahiro Kinoshita, Toshihiko Doi, Kohei Shitara, Hiroyuki Mano, Hiroyoshi Nishikawa
The PD-1 expression balance between effector and regulatory T cells predicts the clinical efficacy of PD-1 blockade therapies
Shogo Kumagai, Yosuke Togashi, Takahiro Kamada, Eri Sugiyama, Hitomi Nishinakamura, Yoshiko Takeuchi, Vitaly Kochin, Kota Itahashi, Yuka Maeda, Shigeyuki Matsui, Takuma Shibahara, Yasuho Yamashita, Takuma Irie, Ayaka Tsuge, Shota Fukuoka, Akihito Kawazoe, Hibiki Udagawa, Keisuke Kirita, Keiju Aokage, Genichiro Ishii, Takeshi Kuwata, Kenta Nakama, Masahito Kawazu, Toshihide Ueno, Naoya Yamazaki, Kōichi Goto, Masahiro Tsuboi, Hiroyuki Mano, Toshihiko Doi, Kohei Shitara, Hiroyoshi Nishikawa
Lapatinib Plus Paclitaxel Versus Paclitaxel Alone in the Second-Line Treatment of <i>HER2</i>-Amplified Advanced Gastric Cancer in Asian Populations: TyTAN—A Randomized, Phase III Study
Taroh Satoh, Rui‐Hua Xu, Hyun Cheol Chung, Guoping Sun, Toshihiko Doi, Jianming Xu, Akihito Tsuji, Yasushi Omuro, Jin Li, Jinwan Wang, Hiroto Miwa, Shukui Qin, Ik‐Joo Chung, Kun‐Huei Yeh, Jifeng Feng, Akihira Mukaiyama, Mikiro Kobayashi, Atsushi Ohtsu, Yung‐Jue Bang